Humanin

Humanin has the longest research history of the three mitochondrial peptides and the most compelling longevity associations derived from population-level data. Despite this long history, most of its mechanistic data comes from animal and cell culture studies. Human trial data for Humanin is described as very limited compared to both SS-31 and MOTS-c.

Humanin is associated with compelling longevity findings derived from population-level observational data, which the speaker describes as among its most notable attributes. However, this population data is not supported by robust mechanistic human trial data, limiting its overall clinical confidence ranking. This makes Humanin's longevity evidence associative rather than interventional.

Despite Humanin's long research history, the speaker clarifies that the majority of its mechanistic data originates from animal models and cell culture (in-vitro) studies rather than human trials. This limits its clinical confidence ranking relative to SS-31 and MOTS-c. No dosage or protocol details are mentioned.

Despite its long research history, the majority of Humanin's mechanistic data comes from animal studies and cell culture (in-vitro) experiments rather than human clinical trials. Human trial data for Humanin is described as very limited, even compared to MOTS-c, which itself has limited human trial progress. This gap between preclinical and clinical evidence is the primary reason for its last-place ranking in clinical confidence.

The speaker provides an explicit evidence-based ranking of three mitochondrial peptides by clinical confidence: SS-31 ranks highest (advanced human RCT data), MOTS-c ranks second (first mitochondrial peptide in clinical trials, promising but limited human data), and Humanin ranks third (longest history but mostly preclinical data). The speaker explicitly states this ranking is not a value judgment on effectiveness or importance, nor does it reflect anecdotal reports.

The speaker provides an explicit evidence-based clinical confidence ranking of three mitochondrial peptides: SS-31 (highest), MOTS-c (promising/intermediate), and Humanin (lowest/most limited human data). The speaker explicitly clarifies this ranking is based solely on the current state of clinical evidence and is not a value judgment on efficacy or importance. Anecdotal reports are also explicitly excluded from this ranking methodology.

Humanin is noted to have the longest research history of the three peptides discussed, predating both SS-31 and MOTS-c in terms of scientific investigation. Despite this longevity in research history, it ranks last in clinical confidence due to the nature and stage of its evidence base. The speaker frames this as a purely evidence-based ranking, not a judgment of importance or effectiveness.